Company intelligence / Profile preview

EVA Therapeutics

Osaka, Osaka Prefecture, Japan

Ownership: Private
Development stage: Other

Overview

EVA Therapeutics is developing EVA-101, a device for enteral oxygen delivery via perfluorodecalin, targeting neonatal and adult patients with respiratory failure. Initial clinical efforts are focused on neonates requiring respiratory assistance in Japan, with ongoing trials in healthy adults expected to finish in March 2025

Therapeutic areas: Pulmonology
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

National Center for Child Health and Development (Japan)Institute of Science Tokyo (formerly Tokyo Medical and Dental University)

Beyond the preview

Go deeper on EVA Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVA Therapeutics.

Explore the full profile